The Latest

  • Approval Is Not the Finish Line: Turning Late-Stage Clinical Evidence Into Real-World Impact
    Approval Is Not the Finish Line: Turning Late-Stage Clinical Evidence Into Real-World Impact

    Late-stage clinical programs establish the evidence required for regulatory evaluation, but they do not guarantee adoption, access, or commercial performance. Translating that evidence into real-world impact requires patient-centered execution and…

  • How Peer Mentors Help Patients Start and Stay on Therapy in Rare Disease
    How Peer Mentors Help Patients Start and Stay on Therapy in Rare Disease

    In rare disease, a missing piece in starting and staying on therapy is often lived perspective. Patients and their care partners may begin rare disease treatment with no peer reference…

  • Six Patient Engagement “Trends” We Should Have Outgrown by 2026
    Six Patient Engagement “Trends” We Should Have Outgrown by 2026

    By Cheryl Lubbert, Reverba Global CEO. A New-Year Perspective on Patient Engagement The biopharma industry talks a good game about patient engagement. We talk about personalization, digital transformation, empowerment, omnichannel…